Dr. Arend Discusses Targets in Endometrial Cancer

Rebecca Arend, MD
Published: Tuesday, Aug 01, 2017



Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.

There was a gynecologic study that showed that the combination of the mTOR inhibitor everolimus (Afinitor) and letrozole provided prolonged benefit in a patient with an mTOR mutation.

Regimens of EZH2 inhibitors in patients with ARID1A mutations, as well as MEK inhibitors, are also in the pipeline and are worth consideration, says Arend.
 
SELECTED
LANGUAGE


Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses targeted therapies in endometrial cancer.

There was a gynecologic study that showed that the combination of the mTOR inhibitor everolimus (Afinitor) and letrozole provided prolonged benefit in a patient with an mTOR mutation.

Regimens of EZH2 inhibitors in patients with ARID1A mutations, as well as MEK inhibitors, are also in the pipeline and are worth consideration, says Arend.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x